WO2025262646 - DOSAGE FORMS OF TROFINETIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
National phase entry is expected:
Publication Number
WO/2025/262646
Publication Date
26.12.2025
International Application No.
PCT/IB2025/056279
International Filing Date
20.06.2025
Title **
[English]
DOSAGE FORMS OF TROFINETIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
[French]
FORMES POSOLOGIQUES DE TROFINÉTIDE ET DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
Applicants **
BIOPHORE INDIA PHARMACEUTICALS PVT. LTD
Inventors
PULLAGURLA, Manik Reddy
ARUTLA, Srinivas
RANGISETTY, Jagadeesh Babu
Priority Data
202441048020
22.06.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1954 | |
| EPO | Filing, Examination, Granting | 11600 | |
| Japan | Filing, Examination, Granting | 2025 | |
| South Korea | Filing, Examination, Granting | 1783 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,102
Contact Us
Abstract[English]
The present invention relates to a stable powder composition for an oral solution or suspension (PFOS) comprising of trofinetide and atleast one or more pharmaceutically acceptable excipients, and process for the preparation thereof. The present invention relates to a stable ready-to-use oral solution comprising of trofinetide and atleast one or more pharmaceutically acceptable excipients, and process for the preparation thereof. The present invention relates to stable dosage forms comprising of trofinetide and atleast one or more pharmaceutically acceptable excipients which is useful in treating a variety of neurodegenerative disorders, autism spectrum disorders, and neurodevelopmental disorders.[French]
La présente invention concerne une composition de poudre stable pour une solution ou suspension orale (PFOS) comprenant du trofinétide et au moins un ou plusieurs excipients pharmaceutiquement acceptables, et son procédé de préparation. La présente invention concerne une solution orale stable prête à l'emploi comprenant du trofinétide et au moins un ou plusieurs excipients pharmaceutiquement acceptables, et son procédé de préparation. La présente invention concerne des formes posologiques stables comprenant du trofinétide et au moins un ou plusieurs excipients pharmaceutiquement acceptables qui sont utiles dans le traitement d'une variété de troubles neurodégénératifs, de troubles du spectre autistique, et de troubles neurodéveloppementaux.